|
Prior to his involvement with Glyconix at its inception in August 2001 from 1989 to 2003, Dr. Pamukcu was a Founder and Director of Cell Pathways, Inc. (CPI), an emerging pharmaceutical company recently acquired by OSI Pharmaceuticals whose mission was to develop drugs directed toward the prevention and treatment of cancer. As Chief Scientific Officer and Executive Vice President of Research and Development at CPI, Dr. Pamukcu directed the basic science, preclinical drug development, clinical research, regulatory programs and various aspects of chemical scale-up and manufacturing over the last decade. Since CPI's founding in 1989, Dr. Pamukcu has be instrumental in raising over $140 million of investment capital and participated in the transformation of CPI from a private to a publicly traded company. Dr. Pamukcu received his B.A. degree from the Johns Hopkins University and his M.D. degree from the University of Wisconsin School of Medicine. He completed his residency in Internal Medicine at Rush-Presbyterian St. Luke's Medical Center prior to his fellowship in Gastroenterology at the University of Chicago. During his fellowship, he co-founded Cell Pathways with one of his patients, Mr. Floyd Nichols, who suffered from Familial Polyposis, the disease which CPI's first drug was designed to treat. Dr. Pamukcu subsequently was appointed Assistant Professor of Medicine at the University of Cincinnati, where, as a consultant, he nurtured Cell Pathways during its infancy. In 1993, Dr. Pamukcu became adjunct faculty at the University of Cincinnati (a position he held until 1995) so that he could devote his efforts full-time to Cell Pathways. Dr. Pamukcu has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group and Scientific Advisory Board of the Hereditary Colon Cancer Association. He was one of twenty-five invited members to the Clinical Trials Summit, a high level think-tank directed at changing the paradigm by which breast cancer drugs are developed, convened by the National Breast Cancer Coalition. He was an invited speaker at the first International GI Malignancy Conference in Israel, a meeting established through the joint efforts of President Bill Clinton and the Israeli Prime Minister. He was most recently honored with addressing the international think-tank of the British Gastroenterology Society, Royal Society of Medicine on GI malignancies and their prevention. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal articles, book chapters and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention and signal transduction systems. He is an inventor on over 280 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention, cancer chemotherapeutics and inflammatory bowel disease. | 